臺灣博碩士論文加值系統

動態對比劑顯影核磁共振影像應用於腫瘤偵測上的主要原理為利用腫瘤血管新生的特性，經由注射對比劑改變組織訊號值，觀察時間訊號曲線，利用定量或半定量方式得到相關參數用來評估攝護腺腫瘤，實際臨床上，攝護腺移行區會發生良性攝護腺增生，是一種富血管性的良性變化，目前診斷技術上最大的困難即為分辨攝護腺腫瘤和良性攝護腺增生，本篇研究希望藉由腫瘤內異質性來區分兩者。
近年，腫瘤內異質性被大家廣泛研究，分布圖分析和紋理分析皆有研究用 來觀察腫瘤異質性，本篇研究使用分布圖分析觀察半定量參數 (流入斜率、延遲期斜率) 分布，比較腫瘤組織和正常組織間的分布參數，將分布參數應用於區分攝護腺腫瘤和良性攝護腺增生。

The principle of dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) applying in tumor detection is based on tumor angiogenesis. DCE-MRI can noninvasively assess tissue vascularity by injecting contrast agent and time intensity curve can be obtained then analyzed by quantitative or semi-quantitative approach.
Benign prostatic hyperplasia (BPH) is a benign condition with hyper-vascularity within the TZ. This benign condition makes that detecting prostate in the transitional zone (TZ) is still a challenge.
The hypothesis in this study is that tumor vascular heterogeneity could help to discriminate the TZ prostate cancer from BPH. In this study, histogram analysis in wash in slope map and delay phase slope map were carried out on the DCE-MRI data of the patients diagnosed with prostate cancer. Several indexes were evaluated to investigate the efficiency on differentiating prostate cancer from BPH.

Contents
摘要 i
致謝 ii
Abstract iii
Contents iv
Chapter 1 Introduction 1
Chapter 2 Theory 4
2.1 Prostate anatomy & pathology 4
2.2 Diagnosis of prostate cancer 5
2.3 Dynamic contrast enhanced MRI 6
Chapter 3 Materials and methods 8
3.1 Patients 8
3.2 MRI 8
3.3 Image Analysis 10
3.3.1 Parametric image 10
3.3.2 Histogram analysis 16
3.3.3 ROI selection 16
3.4 Statistical Analysis 19
Chapter 4 Results 20
4.1 Results from four algorithms 20
4.2 Histogram parameters of normal tissue and cancer 27
4.2.1 Histogram analysis in TZ 27
4.2.2 Histogram analysis in PZ 29
4.3 ROC analysis 31
Chapter 5 Discussion and conclusion 33
Appendix 42
References 43

1. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2015. CA Cancer J Clin, 2015. 65(1): p. 5-29.
2. McNeal, J.E., The zonal anatomy of the prostate. Prostate, 1981. 2(1): p. 35-49.
3. Barentsz, J.O., et al., ESUR prostate MR guidelines 2012. Eur Radiol, 2012. 22(4): p. 746-57.
4. Jackson, A., et al., Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res, 2007. 13(12): p. 3449-59.
5. Yang, X. and M.V. Knopp, Quantifying tumor vascular heterogeneity with dynamic contrast-enhanced magnetic resonance imaging: a review. J Biomed Biotechnol, 2011. 2011: p. 732848.
6. Just, N., Improving tumour heterogeneity MRI assessment with histograms. Br J Cancer, 2014. 111(12): p. 2205-13.
7. Villeirs, G.M., et al., Magnetic resonance imaging anatomy of the prostate and periprostatic area: a guide for radiotherapists. Radiother Oncol, 2005. 76(1): p. 99-106.
8. Bigler, S.A., R.E. Deering, and M.K. Brawer, Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol, 1993. 24(2): p. 220-6.
9. Weidner, N., et al., Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol, 1993. 143(2): p. 401-9.
10. Brawer, M.K., et al., Predictors of Pathological Stage in Prostatic-Carcinoma - the Role of Neovascularity. Cancer, 1994. 73(3): p. 678-687.
11. Padhani, A.R., et al., Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol, 2000. 55(2): p. 99-109.
12. Engelbrecht, M.R., et al., Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology, 2003. 229(1): p. 248-54.
13. Rouviere, O., et al., Characterization of time-enhancement curves of benign and malignant prostate tissue at dynamic MR imaging. Eur Radiol, 2003. 13(5): p. 931-42.
14. Noworolski, S.M., et al., Dynamic contrast-enhanced MRI in normal and abnormal prostate tissues as defined by biopsy, MRI, and 3D MRSI. Magn Reson Med, 2005. 53(2): p. 249-55.
15. Kim, J.K., et al., Wash-in rate on the basis of dynamic contrast-enhanced MRI: usefulness for prostate cancer detection and localization. J Magn Reson Imaging, 2005. 22(5): p. 639-46.
16. Zelhof, B., et al., Description of magnetic resonance imaging-derived enhancement variables in pathologically confirmed prostate cancer and normal peripheral zone regions. BJU Int, 2009. 104(5): p. 621-7.
17. Peng, S.L., et al., Analysis of parametric histogram from dynamic contrast-enhanced MRI: application in evaluating brain tumor response to radiotherapy. NMR Biomed, 2013. 26(4): p. 443-50